Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

The quest for artificial intelligence (AI) began over 70 years ago, with the idea that computers would one day be able to think like us. Ambitious predictions attracted generous funding ...

Drawing tablets come in two forms: pen displays, which include the best drawing tablets with screens for immersive experiences, and pen tablets, which require an external monitor but can be a more ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Artificial intelligence (AI) is ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Efficient data collection and ...

Adobe's dull forecast raises AI monetization doubts, shares fall Adobe forecast second-quarter revenue in line with Wall Street expectations on Wednesday, as it grapples with slower monetization ...

The updates help enterprises deploy AI workloads with more transparency, security, and efficiency.

Are you looking for Microsoft Store in: {0}? I would like information, tips and offers about Microsoft Store and other Microsoft products and services. Click here to ...